INS and diabetes mellitus: While the overall magnitude of the HbA1c lowering effect of sacubitril/valsartan was modest and the overall occurrence of hypoglycemic adverse events was low, clinicians should be aware of the possibility of improved glycemic control and reduced need for insulin, when initiating therapy with sacubitril/valsartan in patients with diabetes.